本帖最后由 老马 于 2012-1-13 21:20 编辑
3 q# H6 B+ T; d* \3 P u7 K U* @8 S: S& [6 `
爱必妥和阿瓦斯丁的比较" G! j) N. E' q0 Q& x, d
9 u% s8 p9 v6 k2 J7 Khttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ H6 W' {3 ^& Y {
+ S3 T2 S( i6 b! T
|0 {( L+ B4 H" m: I8 W _( B5 p9 ehttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 |: c. E# K+ y3 _. H. E: `==================================================2 M( H" x5 o9 d; c. H+ u; f
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, F/ \+ T! f4 E/ Q; Z' R; F. IPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
U1 k/ v2 U# Z- } c" \Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: a3 |- r" h" i0 C8 e+ F: b. a
|